Pharmacology of Combined Mesalzine and Rifaximin Therapy for Inflammatory Bowel Disease

  • Krishna V Prajapati Shree Dhanvantary Pharmacy College
  • Raj A Hasumati Shree Dhanvantary Pharmacy College
  • Vinit C Jain Shree Dhanvantary Pharmacy College
  • Neelam S. Prajapati Shree Dhanvantary Pharmacy College
Keywords: Mesalazine, Rifaximin, inflammatory bowel disease, Pharmacology

Abstract

This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is Used as in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.

Author Biographies

Krishna V Prajapati, Shree Dhanvantary Pharmacy College

Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim,
Surat, India

Raj A Hasumati, Shree Dhanvantary Pharmacy College

Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim,
Surat, India

Vinit C Jain, Shree Dhanvantary Pharmacy College

Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim,
Surat, India

Neelam S. Prajapati, Shree Dhanvantary Pharmacy College

Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim,
Surat, India

Published
2016-05-01
How to Cite
[1]
Prajapati, K., Hasumati, R., Jain, V. and Prajapati, N. 2016. Pharmacology of Combined Mesalzine and Rifaximin Therapy for Inflammatory Bowel Disease. PharmaTutor. 4, 5 (May 2016), 41-45.
Section
Articles